Innovative Treatment Approach Akili's digital medicine delivered through engaging video games presents a novel therapeutic modality, opening opportunities to partner with healthcare providers, insurers, and government agencies interested in innovative, non-pill solutions for cognitive and psychiatric conditions.

FDA Clearance Advantage With recent FDA approval of EndeavorOTC for adults with ADHD, there is a significant market entry point for targeted outreach to clinicians, mental health practitioners, and pharmacies seeking approved digital therapeutics to enhance treatment options.

Expanding Market Appeal Akili's focus on treating multiple conditions such as ADHD, depression, and autism spectrum disorder offers cross-segment sales potential, appealing to a wide range of healthcare and insurance stakeholders interested in comprehensive cognitive health solutions.

Funding and Growth With substantial funding of over $390 million and revenues between $10 million and $25 million, Akili is well-positioned to expand its sales efforts, explore strategic partnerships, and scale commercialization efforts across new markets.

Potential Collaborations Given its focus on neuroscience and sophisticated technology stack, Akili can attract collaboration with technology firms, research institutions, and healthcare organizations looking to leverage digital health innovations for broader treatment dissemination and data collection.